Chemotherapy for osteosarcoma with high-dose methotrexate is effective and outpatient therapy is now possible: Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 11, 2007, Pages 624-625

  Anderson, Pete ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE G2; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; HEARING LOSS; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; ORTHOPEDIC SURGERY; OSTEOSARCOMA; OTOTOXICITY; OUTPATIENT CARE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 35649020710     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0953     Document Type: Short Survey

References (5)

1. Meyers PA et al. (2005) Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: 2004-2011
2. Whelan J et al. (2006) Management of osteosarcoma. Curr Treat Options Oncol 7: 444-455
3. Laginha KM et al. (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11: 6944-6949
4. Lewis M et al. (2007) Hearing loss in children with osteosarcoma [abstract #9517]. J Clin Oncol 25
5. Anderson PM and Pearson M (2006) Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 8: 310-315